Rilotumumab is a fully human monoclonal antibody investigated for the treatment of MET-positive gastric cancer. The aim of this study was to evaluate the potential pharmacokinetic (PK)-based drug-drug interaction (DDI) between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X).
Introduction
Over the past two decades, the hepatocyte growth factor (HGF):MET pathway has been shown to control important cellular functions such as proliferation and survival and to play a critical role in tumour development and metastasis [3] [4] [5] [6] [7] [8] [9] [10] [11] . A number of antagonists that target this pathway have been evaluated as potential anticancer drugs. Some of these agents target the MET receptor while others target the ligand HGF. Some evidence indicates that blocking the activation of the HGF:MET pathway inhibits tumour growth in humans [12] .
Rilotumumab is a fully human monoclonal antibody (immunoglobulin type 2 [IgG2]) against human HGF. It inhibits HGF:MET signalling through neutralization of HGF to block the binding of HGF to its receptor MET [13] . In a Phase 2 study, rilotumumab administered at doses of 7.5 and 15 mg kg À1 in combination with epirubicin, cisplatin and fluoropyrimidine (ECX) once every 3 weeks (Q3W) appeared to improve efficacy outcomes (progression-free survival, overall survival [OS] and objective response rate) without significantly changing the safety profiles compared with ECX alone in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma [14] . In an exploratory biomarker analysis, tumour MET expression was found to have a prognostic and predictive effect on efficacy outcomes [15, 16] . Thus, a double-blind, placebo-controlled Phase 3 trial was conducted to evaluate the efficacy and safety of rilotumumab in combination with ECX for the first-line treatment of patients with MET-positive gastric or GEJ adenocarcinoma. Combination of ECX with rilotumumab appeared to have no impact on rilotumumab pharmacokinetics (PK) in a previous Phase 2 study [14] . However, the impact of rilotumumab on ECX PK has not been evaluated. In this Phase 3 study, we evaluated the PK of rilotumumab and ECX. The primary objective of this clinical study was to determine whether the treatment of rilotumumab in combination with ECX significantly improves OS as compared with rilotumumab-placebo in combination with ECX in subjects with unresectable, locally advanced or metastatic MET-positive gastric or GEJ adenocarcinoma. The objective of this work was also to evaluate the PK-based drug-drug interaction (DDI) potential between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X). The efficacy and safety results from the Phase 3 clinical study will be reported separately.
Methods

Study design and objectives
This analysis was based on data collected in a Phase 3, multicentre, randomized, double-blind, and placebocontrolled study of rilotumumab in combination with epirubicin, cisplatin and capecitabine (ECX) (Clinicaltrials. gov registration # NCT00719550). As one of the secondary objectives of the study, the PK-based DDI potential between rilotumumab and ECX was characterized.
Patient population and drug administration
Patients with MET-positive gastric or GEJ adenocarcinoma were eligible for the study. Tumour MET positivity was assessed by an immunohistochemistry assay by protocolspecified centralized testing. Tumour membrane staining equal to or greater than 25% was defined as MET-positive. Patients at selected sites participated in intensive PK (IPK) assessment for rilotumumab and ECX, while all other patients participated in non-intensive PK (non-IPK) collection. All patients provided written consent prior to participating in the PK substudy, and this study received ethics committee approval.
Rilotumumab was administered as an intravenous (IV) infusion at 15 mg kg À1 Q3W, epirubicin was administered as an IV bolus dose at 50 mg m À2 Q3W, cisplatin was administered as an IV infusion at 60 mg m À2 Q3W, and capecitabine was given as an oral dose at 625 mg m À2 twice daily ( Figure 1 ).
PK sample collection
Rilotumumab PK samples were collected from all subjects. For subjects participating in the IPK assessment, serum samples were collected at pre-dose, end of infusion (EOI), 2, 24, 168 and 336 h after start of infusion at cycle 1; pre-dose on day 1 cycle 2 (504 h after cycle 1 dose); pre-dose and EOI on day 1 of cycles 3, 5 and 7. For subjects participating in the non-IPK assessment, serum samples were collected at pre-dose and EOI on day 1 of cycles 1, 3, 5 and 7. ECX PK samples were only collected from IPK subjects on day 1 of cycle 3. Epirubicin plasma PK samples were collected at end of bolus (EOB), 0.5, 1, 2, 5 and 24 h after dose. Cisplatin plasma PK samples were collected at 0.5, 1, 2, 5 and 24 h after start of infusion. Capecitabine plasma PK samples were collected at 0.5, 1, 2, 5 and 24 h following the morning dose ( Figure 1 ).
Bioanalytical methods
Epirubicin concentrations were analysed using a validated high performance liquid chromatographic method coupled with mass spectrometry detection (HPLC-MS/MS) with a minimum quantifiable plasma concentration of 0.5 ng ml À1 , between-run precision of 3.2-11.9%, and within-run precision of 1.2-6.1% [17] . Total and unbound platinum concentrations were determined using an agilent inductivelycoupled plasma-mass spectrometer (ICP-MS) method with a minimum quantifiable concentration of 40 ng ml À1 , between-run precision of 3.8-5.0%, and within-run precision of 0.9-5.5% [18] . Capecitabine and 5-FU concentrations were analysed using validated HPLC-MS/MS assays with a minimum quantifiable plasma concentration of 10 ng ml À1 , between-run precision of 3.8-6.2%, and within-run precision of 0.4-5.5% [19] .
Rilotumumab concentrations were determined using a validated enzyme-linked immunosorbent assay with a minimum quantifiable serum concentration of 90 ng ml À1 [20] .
PK data analysis
Non-compartmental PK analysis for ECX. PK analyses of epirubicin, capecitabine, 5-FU, total and unbound platinum were performed by non-compartmental analyses (NCA) using Phoenix WinNonlin software (version 6.3, Pharsight, St. Louis, MO, USA). Actual doses administered and actual sampling times were used in the NCA analysis, while nominal times (hours post-dose) were used for presenting data in graphs. The maximum concentration (C max ) and the area under the serum concentration-time curve from time 0 to the time of last quantifiable concentration (AUC last ) were estimated. The study was not statistically powered for DDI evaluation, and no formal statistical testing on PK parameter comparison was planned. To assess the DDI potential between ECX and rilotumumab, C max and AUC of ECX in the presence and absence of rilotumumab, the geometric mean ratios and their 90% confidence intervals (CIs) were derived and compared in the presence and absence of rilotumumab.
Population PK analysis for rilotumumab. PK analysis of rilotumumab was conducted by nonlinear mixed effect modelling [21, 22] with extended least squares regression using NONMEM 7.2 (ICON Development Solutions, Ellicott City, MD, USA). Graphical analysis of rilotumumab, including evaluation of NONMEM outputs, was performed with Tibco Spotfire S+ 8.2.0 (TIBCO Software Inc., Palo Alto, CA, USA).
To evaluate the effect of ECX on rilotumumab PK, the observed rilotumumab concentrations in the presence of ECX were compared with model-predicted concentrations of rilotumumab in the absence of ECX using a previously developed population PK model [23] . Briefly, the population PK model used in this analysis was developed with a sequential approach using PK data from seven Phase 1 and Phase 2 Figure 1 Schema illustration of the schedule of study drug administration and PK sampling studies [21, [24] [25] [26] [27] [28] [29] . The base model was a two-compartment model with the lowest minimum value of objective functions (MVOF) compared with one-and three-compartment models. The model was parameterized by systemic clearance (CL), volume of distribution for the central compartment (Vc), volume of distribution for the peripheral compartment (Vp), and intercompartmental clearance between the central and peripheral compartment (Q). The covariates included in this population PK model were selected using the forward inclusion (MVOF < 6.635, df = 1, P < 0.01), followed by backward elimination (MVOF > 7.879, df = 1, P < 0.005) approach. This previously developed population PK model had been evaluated through visual predictive check and nonparametric bootstrap approaches. Detailed methods about model building and evaluation can be found in the previously published paper [23] .
In this study, an external visual predictive check was performed. Simulations were performed using an equal number of rilotumumab concentrations as observed in ECX arm. Rilotumumab concentrations were predicted for the trial subjects using the same dose and regimen of rilotumumab, and the same PK sampling scheme as the previously developed and validated population PK model. Since the previously developed model from Phase 1 and Phase 2 data did not find ECX to be a significant covariate for PK, validation of the PK data from this study, using the predicted concentrations from the developed model, will demonstrate no ECX effect on rilotumumab PK. As part of the external validation technique, 500 simulated replicates of the original dataset were constructed and simulated. Then, the PK concentrations were binned based on protocol-derived nominal or other time points to maintain an approximately well-balanced distribution of PK concentrations across the bins. The median (95% prediction interval) was computed for the simulated data and compared with the observations.
Results
A total of 609 subjects enrolled in the study, of which 279 subjects had measured PK concentrations for rilotumumab and 75 subjects had measured PK concentrations for ECX.
Among the 279 subjects who received rilotumumab and had measured PK concentrations, 53 subjects had IPK sampling, while the remaining 226 subjects had sparse PK sampling. Data from all these 279 subjects were included in the population PK evaluation for rilotumumab.
Among the 75 subjects who had ECX PK assessment, 44, 45, 45, 35 and 33 subjects had complete PK profiles for epirubicin, total and unbound platinum, capecitabine, and 5-FU, respectively, and were included in the NCA analysis. Other subjects were excluded from the NCA analysis due to missing PK samples or dose deviations.
The dataset for rilotumumab population analysis consisted of a total of 1460 serum concentrations from all subjects who received multiple Q3W IV doses of 15 mg kg À1 rilotumumab. During the preparation and exploration of the dataset, a total of 34 (0.02%) serum concentrations were excluded either as outliers which deviated substantially from adjacent points in the PK time-course, or for being at below the level of quantitation.
The median age of subjects was 59 years and ranged from 19 to 85. The median body weight was 69 kg and ranged from 39 to 120 kg. These ranges were within the observed ranges of the dataset used to build the published model [23] .
PK results of epirubicin
The plasma concentration-time profile of epirubicin in the presence and absence of rilotumumab was comparable by visual inspection, as shown in Figure 2 . Mean (SD) values of epirubicin C max and AUC last in the rilotumumab group were 0.973 (0.799) μg ml À1 and 0.660 (0.372) h μg ml À1 , respectively (Table 1) . These values were similar to those observed in the rilotumumab-placebo group which had mean (SD) C max and AUC last values of 1.15 (0.948) μg ml À1 and 0.777 (0.322) h μg ml À1 , respectively. The geometric mean ratios of C max and AUC last of epirubicin in the presence and absence of rilotumumab were about 0.8, and the 90% CIs included the value of 1.0, indicating co-administration of ECX with rilotumumab had no impact on epirubicin PK.
PK results of total and unbound platinum
The plasma concentration-time profiles of total and unbound platinum in the presence and absence of rilotumumab were similar by visual inspection, as shown in Figure 3 . The geometric mean ratios of C max and AUC last of total and unbound platinum in the presence and absence of Figure 2 Mean (+SD) plasma epirubicin concentration-time profiles in the presence and absence of rilotumumab rilotumumab were between 1.0 and 1.3, and their 90% CIs all included the value of 1.0, indicating that co-administration of ECX with rilotumumab had no impact on exposures of total and unbound platinum.
PK results of capecitabine and 5-FU
The plasma concentration-time profiles of capecitabine and its metabolite 5-FU, in the presence and absence of rilotumumab, overlapped by visual inspection, as shown in Figure 4 . Mean (SD) values of capecitabine C max and AUC last in the rilotumumab group were 2.37 (2.56) μg ml À1 and 4.47 (4.92) h μg ml À1 , respectively (Table 1) . These values were similar to those observed in the placebo group which had mean (SD) C max and AUC last values of 2.82 (4.01) μg ml These values were similar to those observed in the placebo group which had mean (SD) C max and AUC last values of 0.0765 (0.0479) μg ml À1 and 0.130 (0.0558) h μg ml À1 , respectively. The geometric mean ratios of C max and AUC last of capecitabine and 5-FU in the presence and absence of rilotumumab were between 1.1 and 1.5, and most of their 90% CIs included the value of 1.0, except for the AUC ratio of 5-FU which had a lower 90% CI slightly over 1.0. Thus, co-administration of ECX with rilotumumab had limited impact on PK of capecitabine and 5-FU.
Population PK results of rilotumumab
In previous population PK analysis, the pharmacokinetics of rilotumumab was well characterized using an open linear 5-FU, 5-fluorouracil; AUC last , area under the serum concentration-time curve from time 0 to the time of last quantifiable concentration; CI, confidence interval; C max, maximum plasma concentration; SD, standard deviation.
Figure 3
Mean (+SD) plasma total and unbound platinum concentrationtime profiles in the presence and absence of rilotumumab Figure 4 Mean (+SD) plasma capecitabine and 5-FU concentration-time profiles in the presence and absence of rilotumumab two-compartment model [23] . The typical model parameter values (relative standard errors) were 0.184 l day À1 (2.5%), 3.56 l (1.5%), 0.833 l day À1 (12.3%), 2.50 l (6.8%) for systemic clearance (CL), central volume of distribution (V1), intercompartmental clearance (Q) and peripheral volume of distribution (Vp), respectively. The interindividual variabilities were 29.8%, 19.8%, 71.0% and 37.3% for the model parameters CL, Vc, Q and V2, respectively. Body weight and age are the significant covariates of the PK parameters and were included in the final model, while sex, cancer type, coadministration of cotherapy agents, baseline HGF and MET levels, and organ functions did not have an effect on rilotumumab pharmacokinetics [23] .
In this study, the observed rilotumumab concentrations were similar to model-predicted values based on the previously developed model from historical data and the actual PK sampling from this study. The majority of the observed serum rilotumumab concentrations were within the 95% prediction interval and the observed concentrations were symmetrically distributed around the median of the model-predicted concentrations when rilotumumab was administered as a single agent ( Figure 5 ), indicating coadministration of ECX with rilotumumab had no impact on rilotumumab PK.
Discussion
This analysis was based on a pivotal trial to evaluate the efficacy and safety of rilotumumab in combination with ECX for the first-line treatment of patients with MET-positive gastric or GEJ adenocarcinoma. Since only limited information on DDI between rilotumumab and ECX was available from previous clinical trials, this study was designed to assess the DDI potential between rilotumumab and ECX as a secondary objective. The results of the observed ECX PK parameters (C max and AUC last ) in the presence and absence of rilotumumab suggests that rilotumumab had limited impact on ECX PK. The comparison of observed rilotumumab PK concentration with predicted concentration data using the previously developed model based on historical data indicated that ECX had no impact on rilotumumab PK [23] .
The observed lack of DDI between rilotumumab and ECX was expected because rilotumumab, as a monoclonal antibody, is expected to be eliminated by catabolism [13] and ECX, as small-molecule anticancer drugs, are cleared by hepatic and/or renal elimination [24, 25, 30] . The absence of DDI is also consistent with observations from several other clinical trials, in which the PK of rilotumumab was not affected by the co-administration of chemotherapeutic agents (e.g. mitoxantrone, carboplatin, cisplatin, etoposide, epirubicin and capecitabine) or targeted agents (e.g. bevacizumab and motesanib), and meanwhile, the PK of other drugs was not affected by rilotumumab [13, [26] [27] [28] .
ECX is a commonly used drug combination for the treatment of gastric cancers. However, the PK profiles of ECX have not been reported to date when all three compounds are administered together. This is the first study to characterize PK of ECX simultaneously with rilotumumab. While the PK results obtained in this study cannot be directly compared with the results from the literature results ECX PK were reported separately due to different dosing schedules and PK sampling durations, the PK characteristics for ECX observed in this study appeared to be similar to those in other studies [29, 31, 32] .
To evaluate the potential DDI effect of rilotumumab on ECX PK, the geometric mean ratios and 90% CIs between two arms were calculated. Although the ranges of 90% CI of the geometric mean ratios were wide due to the large PK variabilities of ECX, the majority of 90% CIs of geometric mean ratios for C max and AUC last included 1.0, except for 5-FU AUC last . This indicates that co-administration of ECX with rilotumumab therapy had limited impact on the PK of ECX. The 90% CI of the geometric mean ratio for 5-FU AUC last did not include the value 1.0. This may be due to the small sample size.
Since the chemotherapeutic agents ECX have narrow therapeutic ranges, it is important to evaluate DDI potential when in combination with rilotumumab to ensure patient safety [17] . Typically, official PK DDI assessment requires sample size calculation based on inter-and intra-subject variability observed in the PK parameters of interest. Considering the feasibility in this Phase 3 study, approximately 12 evaluable subjects per arm were planned to be achieved in cycle 3, when ECX PK samples were collected. In order to ensure sufficient numbers of subjects in PK subgroups without overenrolment, a real-time PK assessment under blinded conditions was performed to periodically evaluate the PK data. Eventually, 12-26 subjects who enrolled in the PK subgroup in each arm had fully evaluable PK profiles for epirubicin, total and unbound platinum, capecitabine and 5-FU, before ECX PK enrolment was stopped. Since this realtime PK assessment was conducted under blinded conditions, we were unable to fully balance subject distribution between the two arms. However, it helped to manage the subject enrolment for PK assessment over multiple sites.
Figure 5
Observed serum rilotumumab concentrations with 95% prediction interval (PI) and median PI based on prediction-corrected visual predictive check (VPC) Rilotumumab PK samples were collected from all subjects. As there was no rilotumumab alone arm under this Phase 3 setting, a population PK approach was applied to compare the observed rilotumumab PK collected in the treated arm with the predicted PK levels as a monotherapy using a previously developed model from Phase 1 and Phase 2 studies [23] . This population PK approach to characterize the DDI potential of large molecules has become more common in current drug development [33] . In this study, the external validation of the reference model using visual predictive check ( Figure 5 ) demonstrated good predictability of the model developed. Since the data from the Phase 3 study was well described by the population PK model, which did not include ECX co-administration as a significant covariate, this demonstrates no ECX co-administration effect on rilotumumab PK using the population approach.
In conclusion, the results of this study demonstrate that there is no clinically relevant PK DDI between rilotumumab and ECX.
